Cardiovascular disease prevention: lipid lowering therapy for people newly diagnosed with hypertension or T2DM

This indicator covers those patients aged between 25 and 84 years, with a new diagnosis of hypertension or type 2 diabetes recorded in the preceding 12 months (excluding those with pre-existing cardiovascular disease, chronic kidney disease, familial hypercholesterolaemia or type 1 diabetes), who have a recorded cardiovascular risk assessment score of 10% or more in the preceding 12 months: the percentage who are currently treated with a lipid lowering therapy. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes.

Last reviewed: 19 February 2025

This indicator updates and replaces NICE indicator 162.

Next review: 29 February 2028

This indicator will be reviewed using the assessment criteria in appendix B of the NICE indicators process guide when it reaches its review date or the underlying guidance is updated.

How to use NICE indicators and how we develop them

Indicators can be used in a number of different settings to support high quality care. These include:

• identifying where improvements are needed
• setting priorities for quality improvement and support
• creating local performance dashboards
• benchmarking performance against national data
• supporting local quality improvement schemes
• showing progress that local health systems are making on outcomes.

Find out how to use indicators and how we develop them.